66
Participants
Start Date
March 21, 2017
Primary Completion Date
December 31, 2025
Study Completion Date
December 31, 2026
Verteporfin
In the last decade a clinical interest of developing new methods for minimally invasive treatments of organ-confined prostatic malignancies has been pursued. In this study the drug verteporfin for injection (VFI) is to be used with the SpectraCure P18 System (Interstitial multiple diode lasers and IDOSE® Software).
SpectraCure P18 System
Interstitial Photodynamic therapy is provided with the the SpectraCure P18 system
RECRUITING
Memorial Sloan Kettering Cancer Center, New York
RECRUITING
Princess Margaret Cancer Centre, Toronto
RECRUITING
Skåne University Hospital, Malmo
RECRUITING
Reader in Urology, University College London & Honorary Consultant Urological Surgeon, University College London Hospitals Trust, London
SpectraCure AB
INDUSTRY